Rifamycins

A group of ANTI-BACTERIAL AGENTS characterized by a chromophoric naphthohydroquinone group spanned by an aliphatic bridge not previously found in other known ANTI-BACTERIAL AGENTS. They have been isolated from fermentation broths of Streptomyces mediterranei.

Also Known As:

Networked: 416 relevant articles (27 outcomes, 43 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Dooley, Kelly E: 10 articles (01/2022 - 11/2014)
2.	Nuermberger, Eric L: 10 articles (01/2022 - 07/2006)
3.	Peloquin, Charles A: 9 articles (10/2017 - 08/2003)
4.	Converse, Paul J: 7 articles (01/2022 - 05/2011)
5.	Grosset, Jacques H: 6 articles (01/2019 - 07/2006)
6.	DuPont, Herbert L: 6 articles (11/2014 - 04/2005)
7.	Garcia, George A: 4 articles (12/2022 - 06/2013)
8.	Murakami, Katsuhiko S: 4 articles (12/2022 - 06/2013)
9.	Tang, Gong-Li: 4 articles (01/2021 - 01/2018)
10.	Chaisson, Richard E: 4 articles (01/2020 - 10/2003)

Related Diseases

1.	Infections 01/01/2020 - "Because of the remarkable efficacy in treating mycobacterial infections, rifamycin and its derivatives are still first-line antimycobacterial drugs. " 09/01/2008 - "Compound 1, in combination with rifamycin, was especially effective in both infected human macrophages and in a murine model of infection. " 11/01/2006 - "Efficacy of novel rifamycin derivatives against rifamycin-sensitive and -resistant Staphylococcus aureus isolates in murine models of infection." 11/01/2012 - "A comparative kinetic study of rifamycin efficacy was then undertaken, and the results indicated that RPT clears latent 18b infection in mice faster than RIF. " 04/01/2008 - "The aim of this prospective randomized study was to verify the validity of topical rifamycin for prevention of post-VLC umbilical infections. "
2.	Tuberculosis (Tuberculoses) 01/01/2021 - "Rifamycin-sparing regimens appear to be safe and highly efficacious in the treatment of active tuberculosis in lung transplant recipients." 01/01/2020 - "This phase 3 trial formally tests the hypothesis that augmentation of rifamycin exposures can shorten tuberculosis treatment to four months. " 11/01/2009 - "For most patients, values for the area under the plasma concentration-time curve were as low or lower than those associated with treatment failure or relapse and with acquired rifamycin resistance in Tuberculosis Trials Consortium/US Public Health Service Study 23. " 05/15/2005 - "A total of 102 (60%) of 169 patients in the treatment trial participated in the pharmacokinetic substudy, including 7 of 8 patients in whom tuberculosis treatment failure or relapse occurred in association with acquired rifamycin-resistant mycobacteria (hereafter, "ARR failure or relapse"). " 09/08/2023 - "The rifamycins are very active against Mycobacterium tuberculosis, which causes tuberculosis (TB), but inactive against many NTM species. "
3.	Acquired Immunodeficiency Syndrome (AIDS) 03/01/1994 - "Recently, rifamycin derivatives have been discovered that are effective against Mycobacterium avium, which is associated with the AIDS complex. " 01/01/2006 - "Rifamycin-based antituberculosis therapy can cure HIV-related TB and, where available, the introduction of highly active antiretroviral therapy (HAART) has markedly reduced the incidence of AIDS and death. " 05/01/1988 - "Rifabutin (ansamycin; LM427), a semisynthetic rifamycin derivative, inhibits the replication of human immunodeficiency virus type 1, the virus etiologically linked to acquired immunodeficiency syndrome. " 08/01/1999 - "The same 3-drug regimen is also effective therapy for disseminated MAC in AIDS patients, in whom the additional problem of a rifamycin/protease inhibitor interaction may be present. " 01/01/2019 - "Rifamycins are indispensable chemotherapeutics in the treatment of various diseases such as tuberculosis, leprosy, and AIDS-related mycobacterial infections. "
4.	Diarrhea 07/01/2017 - "Moreover, MMX®-rifamycin is being positively tested in the treatment of colonic bacterial infections, including traveler's diarrhea. " 12/31/2019 - "The already-known RNA-synthesis suppressor rifamycin is now also approved for noninvasive Escherichia Coli-caused travelers' diarrhea. " 03/11/2019 - "Rifamycin (Aemcolo) for treatment of travelers' diarrhea." 11/01/2014 - "Rifamycin SV is under development for treatment of travelers' diarrhea (TD) in a new oral formulation, Rifamycin SV MMX (RIF-MMX; Santarus Inc., San Diego, CA, USA), which targets its delivery to the colon, making it a unique rifamycin drug. " 07/01/2011 - "Rifaximin is a nonabsorbable rifamycin derivative with an excellent safety profile and a broad spectrum of antimicrobial activity against a variety of enteropathogens causing acute infectious diarrhea. "
5.	Pulmonary Tuberculosis 11/15/2006 - "We conducted a systematic review of published clinical trials involving adult cohorts with pulmonary tuberculosis treated using 6-mo rifamycin-containing regimens, which were grouped under seven categories ordered by dosing schedules. " 04/01/1992 - "The potential for long-acting rifamycins in the management of pulmonary tuberculosis is discussed." 12/01/1970 - "[Rifomycin in repeated and primary treatment of extensive pulmonary tuberculosis]." 10/05/1970 - "[Rifomycin in the treatment of chronic pulmonary tuberculosis]." 01/01/1969 - "[Rifomycin in the treatment of pulmonary tuberculosis: preliminary note]."

Related Drugs and Biologics

1.	Rifaximin (L 105)
2.	Anti-Bacterial Agents (Antibiotics)
3.	Rifampin (Rifampicin)
4.	Rifabutin (Ansamycin)
5.	Rifamycins
6.	Pyrazinamide
7.	Azithromycin (Zithromax)
8.	ABI 0043
9.	rifapentine (Priftin)
10.	Isoniazid (Ftivazide)

Related Therapies and Procedures

1.	Therapeutics
2.	Culture Diffusion Chambers
3.	Duration of Therapy
4.	Laminectomy
5.	Drug Therapy (Chemotherapy)